Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,662,710 papers from all fields of science
Search
Sign In
Create Free Account
ADR-529
Known as:
ADR 529
, ADR529
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Dexrazoxane
Dexrazoxane hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Carbon nanotubes as a novel drug delivery system for anticancer therapy: a review
S. Kushwaha
,
S. Ghoshal
,
A. Rai
,
Satyawan Singh
2013
Corpus ID: 29554298
Carbon nanotubes (CNTs) were discovered in 1991 and shown to have certain unique physicochemical properties, attracting…
Expand
2001
2001
Oxidative mutagenesis of doxorubicin-Fe(III) complex.
E. Kostoryz
,
D. Yourtee
Mutation research
2001
Corpus ID: 36407044
Highly Cited
1996
Highly Cited
1996
Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
A. Imondi
,
P. Della Torre
,
+5 authors
G. Pinciroli
Cancer research
1996
Corpus ID: 15640210
Dexrazoxane [(DZR), ADR 529, ICRF-187] ameliorates doxorubicin (DOX)-induced cardiotoxicity in animals, and is recommended as a…
Expand
Review
1995
Review
1995
Cardiotoxicity and cardioprotection during chemotherapy.
H. Hochster
,
C. Wasserheit
,
J. Speyer
Current opinion in oncology
1995
Corpus ID: 22887391
Chemotherapy drugs have been reported to cause cardiac side effects including cardiomyopathy, ischemia, arrhythmias, and…
Expand
Highly Cited
1994
Highly Cited
1994
Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and…
G. Gorbsky
Cancer research
1994
Corpus ID: 6486967
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and…
Expand
Highly Cited
1993
Highly Cited
1993
Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and…
M. Sehested
,
P. B. Jensen
,
B. Sorensen
,
B. Holm
,
E. Friche
,
E. Demant
Biochemical pharmacology
1993
Corpus ID: 44941111
Highly Cited
1992
Highly Cited
1992
Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
P. Alderton
,
J. Gross
,
M. Green
Cancer research
1992
Corpus ID: 6457262
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in…
Expand
Highly Cited
1992
Highly Cited
1992
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
H. Hochster
,
L. Liebes
,
+6 authors
J. Speyer
Journal of the National Cancer Institute
1992
Corpus ID: 31498817
BACKGROUND Although doxorubicin is an anticancer agent with a wide spectrum of activity, therapy with this anthracycline must…
Expand
1992
1992
In vitro effects of three iron chelators on mitogen-activated lymphocytes: identification of differences in their mechanisms of action.
D. van Reyk
,
S. Sarel
,
N. Hunt
International journal of immunopharmacology
1992
Corpus ID: 37998827
1992
1992
In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
M. Sobol
,
R. Amiet
,
M. Green
Molecular pharmacology
1992
Corpus ID: 38352132
ADR-529 protects against anthracycline cardiotoxicity, possibly by preventing free radical induction. We hypothesize that this…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE